Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Millio...(ough the use of words or phrases such as...),Health

Date:1/30/2009

ough the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning the closing of the transaction, the expected benefits of the proposed acquisition and expected financial results are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risks that the closing conditions of the offer may not be satisfied, that closing will not occur, or that the closing conditions may take longer to satisfy than anticipated, (ii) the risk that Gen-Probe will not successfully integrate Tepnel or achieve expected strategic or financial benefits, (iii) the risk that an insufficient number of shares of Tepnel will be voted in favor of the transaction, (iv) facts relating to Tepnel that may affect timing, or strategic and other benefits of the proposed acquisition, are unknown to Gen-Probe, and (v) the risk that Gen-Probe may not achieve its expected 2009 growth, revenue, earnings or other financial targets that are assumed in its accretion analysis. The foregoing list sets forth some, but not all, of the factors that could affect the companies' ability to achieve results described in any forward-looking statements. For additional information about risks and uncertainties Gen-Probe faces and a discussion of its financial statements and footnotes, see documents filed with the SEC, including the most recent annual report on Form 10-K and all subsequent periodic reports. Gen-Probe assumes no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent
'/>"/>

SOURCE Gen-Probe Incorporated Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
2. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
3. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
4. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
5. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
6. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
7. Gen-Probe to Webcast Two Upcoming Investor Presentations
8. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
9. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference